Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Using SCS to identify biomarkers of response to immunotherapy in patients with high-risk SMM

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into a recent publication exploring the use of immune single-cell sequencing (SCS) as a prognostic tool in patients with smoldering multiple myeloma (SMM) treated with immunotherapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.